ArticleBMC oral health2025
The effect of Rsk2 on TNFα-mediated bone loss in the TMJ and craniofacial skeleton.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Role of Proinflammatory Cytokines in Temporomandibular Disorders: A Systematic Review.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to investigate the impact of the pro-osteoblastogenic ERK-activated ribosomal S6 kinase (Rsk2) on Tumor necrosis factor (TNF)α-induced bone loss in the craniofacial system, focusing on its role in rheumatoid arthritis (RA). The objective is to understand whether Rsk2, previously shown to have protective effects in long bones against TNFα-induced bone resorption, exhibits similar effects in the craniofacial region. MATERIALS: , and Methods. The study compares mice with TNFα overexpression, Rsk2 knockout mice, and a combination of TNFα, and Rsk2 knockout mice using detailed micro-computed tomography coupled with landmark based morphometric analysis, and classical histology. The overall skull morphology, mandible shape, and the temporomandibular joint were examined. Additionally, histological sections were utilized to examine the synovial membrane.
resultsCombining TNFα, and Rsk2 deficiency does not further alter overall skull shape compared to TNFα alone. TNFα overexpression shortens the mandibular ramus, exacerbated by Rsk2 absence. Micro-computed tomography (µCT) reveals significant temporomandibular joint damage from TNFα, independent of Rsk2. However, histological sections show increased synovial membrane thickness with TNFα, heightened in the absence of Rsk2.
conclusionsRsk2 mitigates TNFα-induced effects on mandibular ramus length in the craniofacial system but has limited impact on the temporomandibular joint, except for synovial membrane thickness. Overall, Rsk2 demonstrates a weaker preventive effect on TNFα-induced craniofacial bone loss compared to its established role in the appendicular skeleton. CLINICAL RELEVANCE: This study highlights regional differences in Rsk2's protective mechanisms, emphasizing the need for further exploration of the underlying mechanisms for these disparities. Understanding these regional differences can be crucial for the development of targeted therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.